Medicinal chemistry approaches to personalized medicine / edited by Karen Lackey and Bruce D. Roth.

Format:

Book

Contributor:

Lackey, Karen.

Roth, Bruce D.

Series:

Methods and principles in medicinal chemistry ; v. 59.

Methods and Principles in Medicinal Chemistry ; Volume 59

Language:

English

Subjects (All):

Pharmaceutical chemistry.

Drugs--Synthesis.

Drugs.

Physical Description:

1 online resource (407 p.)

Edition:

1st ed.

Place of Publication:

Weinheim an der Bergstrasse, Germany : Wiley-VCH, 2014.

Language Note:

English

Summary:

Edited by two famous medicinal chemists who have pioneered the development of personalized therapies in their respective fields, this authoritative analysis of what is already possible is the first of its kind, and the only one to focus on drug development issues.Numerous case studies from the first generation of ""personalized dugs"" are presented, highlighting the challenges and opportunities for pharmaceutical development. While the majority of these examples are taken from the field of cancer treatment, other key emerging areas, such as neurosciences and inflammation, are also covered.

Contents:

Medicinal Chemistry Approaches to Personalized Medicine; Contents; List of Contributors; Foreword; Preface; A Personal Foreword; Acronyms; 1 Medicinal Chemistry Approaches to Creating Targeted Medicines; 1.1 Introduction; 1.2 Role of Medicinal Chemistry in Drug Discovery; 1.3 Evolution of Molecular Design for Subsets of Patients; 1.4 Combinations for Effective Therapies; 1.5 Biomarkers in Targeting Patients; 1.6 Emerging Field of Epigenetics; 1.7 Systems Chemical Biology; 1.8 Theranostics and Designing Drug Delivery Systems; 1.9 Rapid Progress in Further Personalizing Medicine Expected

References 2 Discovery of Predictive Biomarkers for Anticancer Drugs; 2.1 Introduction; 2.2 "Oncogene Addiction" as a Paradigm for Clinical Implementation of Predictive Biomarkers; 2.3 Cancer Cell Lines as a Model System for Discovery of Predictive Biomarkers; 2.3.1 Historical Application of Cell Lines in Cancer Research; 2.3.2 Biomarker Discovery Using Cell Line Models; 2.3.3 Cell Lines as Models of Human Cancer; 2.3.4 Challenges and Limitations of Cell Line Models; 2.4 Modeling Drug Resistance to Discover Predictive Biomarkers

2.5 Discovery of Predictive Biomarkers in the Context of Treatment Combinations 2.6 Discovery of Predictive Biomarkers for Antiangiogenic Agents; 2.6.1 Challenges; 2.6.2 Pathway Activity as a Predictor of Drug Efficacy; 2.6.3 Predicting Inherent Resistance; 2.6.4 On-Treatment Effects as a Surrogate of Drug Efficacy; 2.6.5 Summary; 2.7 Gene Expression Signatures as Predictive Biomarkers; 2.7.1 Signature Discovery: Unsupervised Clustering; 2.7.2 Diagnostic Development: Supervised Classification; 2.7.3 Summary; 2.8 Current Challenges in Discovering Predictive Biomarkers

2.8.1 Access to Tumor Cells Is Limited during Treatment 2.8.2 Drivers and Passengers; 2.8.3 Epigenetic Regulation Adds Another Layer of Complexity; 2.8.4 Many Oncoproteins and Tumor Suppressors Undergo Regulatory Posttranslational Modifications; 2.9 Future Perspective; References; 3 Crizotinib; 3.1 Introduction; 3.2 Discovery of Crizotinib (PF-02341066) [40]; 3.3 Kinase Selectivity of Crizotinib; 3.4 Pharmacology of Crizotinib [45,46]; 3.5 Human Clinical Efficacies of Crizotinib; 3.6 Summary; References

4 Discovery and Development of Vemurafenib: First-in-Class Inhibitor of Mutant BRAF for the Treatment of Cancer 4.1 Background; 4.2 Discovery and Development of Vemurafenib (PLX4032); 4.3 Pharmacology; 4.4 Clinical Efficacy and Safety; 4.5 Companion Diagnostic (cobas 4800) Development; 4.6 Synthesis; 4.6.1 Discovery Route(s); 4.6.2 Process Route; 4.7 Summary; References; 5 Targeting Basal-Cell Carcinoma: Discovery and Development of Vismodegib (GDC-0449), a First-in-Class Inhibitor of the Hedgehog Pathway; 5.1 Introduction; 5.2 Hedgehog and Basal-Cell Carcinoma

5.3 Cyclopamine as an SMO Antagonist

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on online resource; title from PDF title page (ebrary, viewed December 11, 2013).

ISBN:

9783527677276

3527677275

9783527677252

3527677259

9783527677283

3527677283

OCLC:

864744144